In patients with type 2 diabetes and heart failure, those assigned oral semaglutide had reduced risk for heart failure events ...

After decades of misdiagnosis and missed signals, researchers are finally starting to close the gender gap that has long ...

Heart disease remains the leading cause of death for women. Despite advancements in awareness and research, gaps remain in ...

Researchers created a human liver tissue model that reproduces early metabolic dysfunction-associated steatotic liver disease ...

Heart & Stroke has released a new report offering a clear picture of the growing risks to heart and brain health in Canada.

On behalf of the CardiAMP HF investigators, the presentation will be made by Dr. Amish Raval, M.D., Professor of Medicine at UW School of Medicine and Public Health and CardiAMP HF Trial National ...

The intake of oral semaglutides such as Wegovy or Rybelsus among adults with type 2 diabetes (T2D) was associated with a reduced risk of heart failure (HF) compared to those who took a placebo, ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by a ...

"Clinical practice must move beyond the outdated notion that women are simply 'small men.'" ...